An Ancillary Study Protocol to GlaxoSmithKline Phase IIb RTS,S/AS01E Malaria Vaccine Trial (Study Number 204889 [MALARIA-094]) Entitled, "Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 30 May 2019 Planned End Date changed from 15 Dec 2022 to 21 Jun 2021.
- 30 May 2019 Planned primary completion date changed from 25 Nov 2022 to 21 Jun 2021.
- 30 May 2019 Status changed from recruiting to active, no longer recruiting.